|
🐜
|
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study
12 auth.
D. Hosking,
S. Adami,
D. Felsenberg,
J. Andia,
M. Välimäki,
L. Benhamou,
...
J. Reginster,
Carol Yacik,
Andrea Rybak-Feglin,
R. Petruschke,
L. Zaru,
A. Santora
|
6 |
2003 |
6
🐜
|
|
🐢
|
Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
7 auth.
J. Adachi,
R. Faraawi,
M. O'Mahony,
Arun Nayar,
R. Massaad,
Judith K. Evans,
...
Carol Yacik
|
3 |
2009 |
3
🐢
|
|
🐜
|
Efficacy and safety of the contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive in Chinese women: a 1-year randomised trial
12 auth.
G. Fan,
M. Ren,
W. Di,
P. Su,
Q. Chang,
Shuying Wu,
...
Yun Qin,
T. Korver,
M. Marintcheva-Petrova,
Carol Yacik,
C. Mccrary Sisk,
Guoqin Wang
|
3 |
2016 |
3
🐜
|
|
🐬
|
Safety and efficacy of the NuvaRing® Applicator in healthy females: a multicenter, open-label, randomized, 2-period crossover study.
R. Feldman,
T. Frenkl,
Carol Yacik,
Yinna Wang,
M. Fox
|
2 |
2016 |
2
🐬
|
|
🐜
|
Once weekly alendronate produces a greater increase in bone mineral density than daily risedronate
9 auth.
D. Hosking,
S. Adami,
D. Felsenberg,
J. Reginster,
J. Cannata,
M. Välimäki,
...
A. Santora,
Carol Yacik,
L. Zaru
|
0 |
2003 |
0
🐜
|
|
🐬
|
An Open-Label, Randomized, Two-Period Crossover Study of the NuvaRing Applicator in Healthy Women [8N]
R. Feldman,
T. Frenkl,
Carol Yacik,
Yinna Wang,
M. Fox
|
0 |
2016 |
0
🐬
|
